Response to: “Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary Arteries”

Abstract

Get full access to this article

View all access options for this article.

References

Muzurović

Zečević

Mantzoros

CS.

Integrating noninvasive liver indices into risk stratification of myocardial infarction with non-obstructive coronary arteries. Angiology. 2026. doi:10.1177/00033197261441899

Küçükukur

Binici

Prognostic value of FIB-4 index and non-alcoholic fatty liver disease in myocardial infarction with non-obstructive coronary arteries: a prospective cohort study. Angiology. 2026. doi:10.1177/00033197261427829

Zhang

Chen

Zhu

Peng

Jin

Yin

Prognostic value of the FIB-4 index in patients with myocardial infarction with non-obstructive coronary arteries. Int J Cardiol. 2026;445:134045.

Rinella

Lazarus

Ratziu

, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.

Hagstrom

Vessby

Ekstedt

Shang

99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76-e77.

Kokkorakis

Muzurovic

Volcanšek

, et al. Steatotic liver disease: pathophysiology and emerging pharmacotherapies. Pharmacol Rev. 2024;76:454-499.

Kokkorakis

Folkertsma

Forte

Wolffenbuttel

BHR

van Dam

Mantzoros

CS.

GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies. Metabolism. 2025;163:156047.

Mantovani

Csermely

Petracca

, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-913.